KCR Expands in UK & Germany and Moves on to France
KCR has opened new offices in London and Berlin, and is now turning its attention to France.
KCR, the CRO operating in 18 countries in Europe as well as the US, has opened new offices in London and Berlin, and is now turning its attention to France.
“I am very excited seeing KCR strengthening its visibility across Western Europe, particularly in the UK and Germany, where we have already been enjoying partnerships with locally based or represented companies,” says Mike Jagielski, CEO of KCR. “Having our own entities registered in these countries will make our collaboration even stronger. It will also equip KCR with local law benefits and make our business cooperation easier. The next country we will aim for is France.”
KCR has operated in Central and Eastern Europe and the Commonwealth of Independent States since 1997. Having a local team in each of the offices gives the company insight into local regulations, and has also helped to build extensive relationships with key opinion leaders and principal investigators, according to the CRO.
KCR offers three types of professional contract research services: clinical development services, functional service provision and post-marketing clinical services, in a wide spectrum of therapeutic areas.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
